Treatment of Nonresponders to Oral Sumatriptan With Zolmitriptan and Rizatriptan: A Comparative Open Trial
Article first published online: 25 DEC 2001
Headache: The Journal of Head and Face Pain
Volume 40, Issue 6, pages 464–465, June 2000
How to Cite
Mathew, N. T., Kailasam, J., Gentry, P. and Chernyshev, O. (2000), Treatment of Nonresponders to Oral Sumatriptan With Zolmitriptan and Rizatriptan: A Comparative Open Trial. Headache: The Journal of Head and Face Pain, 40: 464–465. doi: 10.1046/j.1526-4610.2000.00069.x
- Issue published online: 25 DEC 2001
- Article first published online: 25 DEC 2001
- Accepted for publication December 26, 1999.
In order to study the effect of zolmitriptan and rizatriptan in oral sumatriptan nonresponders (defined as lack of response in three or more of five attacks), 56 patients were studied in an open trial in a crossover fashion. Both zolmitriptan, 5 mg, and rizatriptan, 10 mg, were effective in the majority of sumatriptan nonresponders. The response to rizatriptan, 10 mg, appeared to be better than to zolmitriptan, 5 mg. Approximately 19% of sumatriptan nonresponders remained nonresponders to both zolmitriptan and rizatriptan.